The following press release was issued by the FDA. While the seriousness and pain of bone fractures is significant, the side effect profiles of this drug sound pretty serious. What is the risk/benefit ratio? Is the trade-off worth it? We would love to hear from women who are making these choices.
JUNE 1, 2010: The U.S. Food and Drug Administration today approved Prolia, an injectable treatment for postmenopausal women with osteoporosis who are at high risk for fractures.
Osteoporosis is a disease in which the bones become weak and are more likely to break. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, 80 percent of the people in the United States with osteoporosis are women. One out of every two women over age 50 will break a bone in their lifetime due to osteoporosis.